Solanezumab

Drug Profile

Solanezumab

Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly; Anti-Aβ monoclonal antibody - Eli Lilly; LY-2062430

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 16 Jul 2017 Pharmacodynamics data from the phase III EXPEDITION3 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 16 Jul 2017 Adverse events data from the phase III EXPEDITION, EXPEDITION2 and EXPEDITION3 trials in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 16 Jul 2017 Adverse events data from the phase III EXPEDITION3 trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top